Blocking NF-κB as a potential strategy to treat adult T-cell leukemia/lymphoma

Drug News and Perspectives

Volumn 19, Issue 4, 2006, Pages 201-209

  Horie, Ryouichi ^a,d   Watanabe, Toshiki ^b   Umezawa, Kazuo ^c  

^a KITASATO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ARSENIC; BORTEZOMIB; CYTOKINE; DEHYDROXYMETHYLEPOXYQUINOMICIN; EPOXYQUINOMICIN C; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; I KAPPA B; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; PANEPOXYDONE; RETINOIC ACID; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CYCLOHEXANONE DERIVATIVE;

APOPTOSIS; CANCER GROWTH; CELL TRANSPLANTATION; CELL TRANSPORT; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IN VITRO STUDY; LATENT VIRUS INFECTION; LD 50; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NONHUMAN; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; PROTEIN TRANSPORT; REVIEW; T CELL LEUKEMIA; T CELL LYMPHOMA; TREATMENT INDICATION; VIRUS TRANSMISSION; ADULT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; PATHOLOGY;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CYCLOHEXANONES; HUMANS; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; LYMPHOMA, T-CELL; NF-KAPPA B;

EID: 33748935149     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2006.19.4.985934     Document Type: Review

References (49)

1. Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K., Uchino, H. Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 1977, 50: 481-92.
2. Hinuma, Y., Nagata, K., Hanaoka, M. et al. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A 1981, 78: 6476-80.
3. Proietti, F.A., Carneiro-Proietti, A.B., Catalan-Soares, B.C., Murphy, E.L. Global epidemiology of HTLV-1 infection and associated diseases. Oncogene 2005, 24: 6058-68.
4. Yamaguchi, K. and Watanabe, T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol 2002, 76(Suppl 2): 240-5.
5. Okamoto, T., Ohno, Y., Tsugane, S., et al. Multi-step carcinogenesis model for adult T-cell leukemia. Jpn J Cancer Res 1989, 80: 191-5.
6. Mortreux, F., Gabet, A.S., Wattel, E. Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia 2003, 17: 26-38.
7. Yoshida, M., Miyoshi, I., Hinuma, Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A 1982, 79: 2031-5.
8. Yoshida, M. Multiple viral strategies of HTLV-I for dysregulation of cell growth control. Annu Rev Immunol 2001, 19: 475-96.
9. Tamiya, S., Matsuoka, M., Etoh, K. et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood 1996, 88: 3065-73.
10. Furukawa, Y., Kubota, R., Tara, M., Izumo. S., Osame, M. Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia. Blood 2001, 97: 987-93.
11. Koiwa, T., Hamano-Usami, A., Ishida, T. et al. 5′-long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo. J Virol 2002, 76: 9389-97.
12. Watanabe, T. HTLV-1-associated diseases. Int J Hematol 1997, 66: 257-78.
13. Yamada, Y., Tomonaga, M., Fukuda, H. et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001, 113: 375-82.
14. Utsunomiya, A., Miyazaki, Y., Takatsuka, Y. et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 27: 15-20.
15. Kami, M., Hamaki, T., Miyakoshi, S. et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. Br J Haematol 2003, 120: 304-9.
16. Huang, M.E., Ye, Y.C., Chen, S.R. et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72: 567-72.
17. Radford, I.R. Imatinib. Novartis. Curr Opin Investig Drugs 2002, 3: 492-9.
18. Horie, R., Watanabe, T., Morishita, Y. et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 2002, 21: 2493-503.
19. Mori, N., Fujii, M., Ikeda, S. et al. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 1999, 93: 2360-8.
20. Chen, F.E. and Ghosh, G. Regulation of DNA binding by Rel/NF-kappaB transcription factors: Structural views. Oncogene 1999, 18: 6845-52.
21. Ghosh, S., May, M.J. and Kopp, E.B. NF-kappaB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16: 225-60.
22. Pahl, H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999, 18: 6853-66.
23. Baldwin, A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001, 107: 241-6.
24. Sun, S.C. and Ballard, D.W. Persistent activation of NF-kappaB by the tax transforming protein of HTLV-1: Hijacking cellular IkappaB kinases. Oncogene 1999, 18: 6948-58.
25. Chu, Z.L., Shin, Y.A., Yang, J.M., DiDonato, J.A. and Ballard, D.W. IKKgamma mediates the interaction of cellular IkappaB kinases with the tax transforming protein of human T cell leukemia virus type 1. J Biol Chem 1999, 274: 15297-300.
26. Harhaj, E.W. and Sun, S.C. IKKgamma serves as a docking subunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein. J Biol Chem 1999, 274: 22911-4.
27. Jin, D.Y., Giordano, V., Kibler, K.V., Nakano, H. and Jeang, K.T. Role of adapter function in oncoprotein-mediated activation of NF-kappaB. Human T-cell leukemia virus type I Tax interacts directly with IkappaB kinase gamma. J Biol Chem 1999, 274: 17402-5.
28. Xiao, G., Cvijic, M.E., Fong, A. et al. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: Evidence for the involvement of IKKalpha. EMBO J 2001, 20: 6805-15.
29. Pomerantz, J.L. and Baltimore, D. Two pathways to NF-kappaB. Mol Cell 2002, 10: 693-5.
30. Hayden, M.S. and Ghosh, S. Signaling to NF-kappaB. Genes Dev 2004, 18: 2195-224.
31. Furukawa, Y., Osame, M., Kubota, R., Tara, M. and Yoshida, M. Human T-cell leukemia virus type-1 (HTLV-1) Tax is expressed at the same level in infected cells of HTLV-1-associated myelopathy or tropical spastic paraparesis patients as in asymptomatic carriers but at a lower level in adult T-cell leukemia cells. Blood 1995, 85: 1865-70.
32. Miura, H., Maeda, M., Yamamoto, N. and Yamaoka, S. Distinct IkappaB kinase regulation in adult T cell leukemia and HTLV-1-transformed cells. Exp Cell Res 2005, 308: 29-40.
33. Higuchi, M., Matsuda, T., Mori, N. et al. Elevated expression of CD30 in adult T-cell leukemia cell lines: Possible role in constitutive NF-kappaB activation. Retrovirology 2005, 2: 29.
34. Epinat, J.C. and Gilmore, T.D. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 1999, 18: 6896-909.
35. Ni, H., Ergin, M., Huang, Q. et al. Analysis of expression of nuclear factor kappa B (NF-kappaB) in multiple myeloma: Down-regulation of NF-kappa B induces apoptosis. Br J Haematol 2001, 115: 279-86.
36. Furman, R.R., Asgary, Z., Mascarenhas, J.O., Liou, H.C. and Schattner, E.J. Modulation of NF-kappaB activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000, 164: 2200-6.
37. Bargou, R.C., Leng, C., Krappmann, D. et al. High-level nuclear NF-kappaB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996, 87: 4340-7.
38. Hironaka, N., Mochida, K., Mori, N., Maeda, M., Yamamoto, N. and Yamaoka, S. Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells. Neoplasia 2004, 6: 266-78.
39. Mori, N., Yamada, Y., Ikeda, S. et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-1-infected T-cell lines and primary adult T-cell leukemia cells. Blood 2002, 100: 1828-34.
40. Satou, Y., Nosaka, K., Koya, Y., Yasunaga, J.I., Toyokuni, S. and Matsuoka, M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004, 18: 1357-63.
41. Nasr, R., Rosenwald, A., El-Sabban, M.E. et al. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003, 101: 4576-82.
42. Matsumoto, N., Ariga, A., To-e, S. et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 2000, 10: 865-9.
43. Matsumoto, N., Iinuma, H., Sawa, T. et al. Epoxyquinomicins A, B, C and D, new antibiotics from Amycolatopsis. II. Effect on type II collagen-induced arthritis in mice. J Antibiot (Tokyo) 1997, 50: 906-11.
44. Ariga, A., Namekawa, J., Matsumoto, N., Inoue, J. and Umezawa, K. Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappaB by dehydroxymethylepoxyquinomicin. J Biol Chem 2002, 277: 24625-30.
45. Watanabe, M., Ohsugi, T., Shoda, M. et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 2005, 106: 2462-71.
46. Pierce, J.W., Schoenleber, R., Jesmok, G. et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphoiylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997, 272: 21096-103.
47. Ohsugi, T., Kumasaka, T., Ishida, A. et al. In vitro and in vivo antitumor activity of the NF-kappaB inhibitor DHMEQ in the human. T-cell leukemia virus type I-infected cell line, HUT-102. Leuk Res 2006, 30: 90-7.
48. Ohsugi, T., Horie, R., Kumasaka, T. et al. In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis 2005, 26: 1382-8.
49. Wattel, E., Vartanian, J.P., Pannetier, C. and Wain-Hobson, S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 1995, 69: 2863-8.